Nephroprotection by SGLT2i in CKD Patients: May It Be Modulated by Low-Protein Plant-Based Diets?

Sodium-glucose-transporter 2 inhibitors (SGLT2i) are a new class of anti-diabetic drugs that in large trials such as CREDENCE have shown also a reduction of glomerular hyperfiltration and albuminuria in type 2 diabetic patients. Hence, the interest toward SGLT2i is focused toward this potential neph...

Full description

Bibliographic Details
Main Authors: Adamasco Cupisti, Domenico Giannese, Diego Moriconi, Claudia D'Alessandro, Massimo Torreggiani, Giorgina B. Piccoli
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-12-01
Series:Frontiers in Medicine
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2020.622593/full